"Synergy Search" Lies Behind AZ's Combined CV, Diabetes and Renal Ops
The head of AstraZeneca's newly combined cardiovascular, metabolic diseases and renal franchise says his mission is to align and find synergies for the three therapeutic areas.
You may also be interested in...
Novo Nordisk is targeting obesity as a key disease market, but its CEO says global alliances are needed in future to help fight the global pandemic, including the food industry.
With diabetes therapeutics adding cardiovascular risk reduction claims, Novartis's heart failure drug Entresto could face pressure from new fronts – just as sales start to take off.
AstraZeneca will cut its sales forecasts for Brilinta after the therapy failed to beat the older blood thinner clopidogrel in the comparison EUCLID study in peripheral artery disease.